Article

Expansion on Stromal Cells Preserves the Undifferentiated State of Human Hematopoietic Stem Cells Despite Compromised Reconstitution Ability

Department of Molecular, Cell and Developmental Biology, University of California Los Angeles, Los Angeles, California, United States of America.
PLoS ONE (Impact Factor: 3.23). 01/2013; 8(1):e53912. DOI: 10.1371/journal.pone.0053912
Source: PubMed

ABSTRACT

Lack of HLA-matched hematopoietic stem cells (HSC) limits the number of patients with life-threatening blood disorders that can be treated by HSC transplantation. So far, insufficient understanding of the regulatory mechanisms governing human HSC has precluded the development of effective protocols for culturing HSC for therapeutic use and molecular studies. We defined a culture system using OP9M2 mesenchymal stem cell (MSC) stroma that protects human hematopoietic stem/progenitor cells (HSPC) from differentiation and apoptosis. In addition, it facilitates a dramatic expansion of multipotent progenitors that retain the immunophenotype (CD34+CD38-CD90+) characteristic of human HSPC and proliferative potential over several weeks in culture. In contrast, transplantable HSC could be maintained, but not significantly expanded, during 2-week culture. Temporal analysis of the transcriptome of the ex vivo expanded CD34+CD38-CD90+ cells documented remarkable stability of most transcriptional regulators known to govern the undifferentiated HSC state. Nevertheless, it revealed dynamic fluctuations in transcriptional programs that associate with HSC behavior and may compromise HSC function, such as dysregulation of PBX1 regulated genetic networks. This culture system serves now as a platform for modeling human multilineage hematopoietic stem/progenitor cell hierarchy and studying the complex regulation of HSC identity and function required for successful ex vivo expansion of transplantable HSC.

Download full-text

Full-text

Available from: Ben Van Handel, Jul 03, 2014
    • "In addition, the understanding of AML physiopathology has been limited by the lack of culture conditions preventing the spontaneous differentiation or death of primary AML cells in vitro (Pabst et al, 2014). To support AML-ICs function ex vivo we optimized a co-culture system based on OP9- M2 cells, previously described as supporting HSCs function (Magnusson et al, 2013). To evaluate this system, we cultured five primary AML samples with or without near-confluence irradiated OP9-M2 cells, supplementing the culture medium with cytokines required for HSCs and myeloid development (stem cell factor, thrombopoietin, Flt3-ligand, interleukin 3 and 6). "

    No preview · Article · Nov 2015 · British Journal of Haematology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Leukemic stem cells (LSCs) are considered a major cause of relapse in acute myeloid leukemia (AML). Defining pathways that control LSC self-renewal is crucial for a better understanding of underlying mechanisms and for the development of targeted therapies. However, currently available culture conditions do not prevent spontaneous differentiation of LSCs, which greatly limits the feasibility of cell-based assays. To overcome these constraints we conducted a high-throughput chemical screen and identified small molecules that inhibit differentiation and support LSC activity in vitro. Similar to reports with cord blood stem cells, several of these compounds suppressed the aryl-hydrocarbon receptor (AhR) pathway, which we show to be inactive in vivo and rapidly activated ex vivo in AML cells. We also identified a compound, UM729, that collaborates with AhR suppressors in preventing AML cell differentiation. Together, these findings provide newly defined culture conditions for improved ex vivo culture of primary human AML cells.
    No preview · Article · Feb 2014 · Nature Methods
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cell-based therapies hold a great promise for treatment of a wide array of tragic diseases. Specifically, the use of cellular vehicle platforms emerges as a powerful strategy for targeted delivery of therapeutics to sites of disease. In this chapter, we first review the success and current challenges of different cell therapies, focusing on pancreatic islet transplantation as well as multiple types of stem cell therapies. We then shift our discussion to cellular delivery systems. Efficient cell targeting to desired sites is a crucial aspect towards effective use of such platforms. Accordingly, we thoroughly discuss a variety of cell engineering strategies to improve cell targeting to sites of interest. We then discuss key aspects of cellular delivery, including the types and characteristics of different nanosystems, candidate therapeutic agents and cell types suitable for this approach. Finally, we conclude with a case study of Trojan Horse cell-based cancer therapy.
    No preview · Chapter · Jun 2014
Show more